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An effective and inexpensive protocol for producing cytochalasins A and B is being disclosed to propose a viable
method by which to examine the in vivo antineoplastic activity of these congeners in preclinical tumor-bearing
mammalian models. In addition, we determine the maximum tolerated doses of cytochalasin B using multiple
routes and formulations, characterize the tissue distribution of intravenous bolus cytochalasin B, and assess the
in vivo antineoplastic activity of cytochalasin B in comparison in doxorubicin in Balb/c mice challenged
intradermally with M109 murine lung carcinoma. We also examine the effects of cytochalasin B against several
other murine neoplastic cell lines (Lewis lung, LA4, B16F10, and M5076). Finally, we examine a potential
mechanism of the antimetastatic activity of cytochalasin B by observing the effects of the agent on the secretion
of N-acetylglucosaminidase (GlcNACase) by B16BL6 and B16F10 murine melanomas in vitro. The results of the
study can be summarized as follows: 1) Cytochalasin B can be safely administered intravenously, intraperitoneally,
and subcutaneously in murine models, with the maximum tolerated dose of all routes of administration being
increased by liposome encapsulation. 2) Cytochalasin B can significantly inhibit the growth of tumors in mice
challenged with M109, Lewis lung, LA4, B16F10, or M5076, producing long-term survival against lung carcinomas
and adenocarcinomas (M109, Lewis lung, and LA4) and B16F10 melanoma, but not M5076 sarcoma. These
effects were comparable to intraperitoneally administered doxorubicin. 4) Low concentrations of cytochalasin B
inhibit the secretion of GlcNACase, indicating that cytochalasin B may inhibit metastatic progression by
mechanisms not directly associated with its influence on cell adhesion and motility.
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Microtubule-directed agents have long been used in cancer
chemotherapy because of their ability to interfere with chromosome
congression and the proper segregation of chromosomes, thereby
invoking G2/M arrest and other aberrant characteristics that
eventually potentiate apoptosis. In addition to these traditional
mitotic inhibitors, cell biology studies have elucidated a tremendous
diversity of cytoskeletal-directed agents that affect the two other
components of the cytoskeleton (microfilaments and intermediate
filaments), many of which exert potent antineoplastic activity [1].
However, despite this diversity of cytoskeletal-directed agents
available to oncologists, all currently approved cytoskeletal-directed
agents used in the clinic have microtubule-based mechanisms [1].
Although it is true that these compounds act by distinct mechanisms
(epothilones and taxanes stabilize microtubules, whereas eribulin andvinca alkaloids disrupt polymerization), they all are microtubule
directed and target nuclear DNA replication in dividing cells.
It has been demonstrated that substantial differences exist between
the microfilament biochemistry of normal cells and their neoplastic
counterparts [1–3] and that these differences affect not only nuclear
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detachment, and cell motility. These diverse cellular properties
affected by actin polymerization suggest that agents affecting
microfilament biochemistry should elicit notable antineoplastic
activity as single agents and in combination with other agents and
treatment modalities.
Cytochalasins are mycogenic toxins known to disrupt the
formation of filamentous (F)-actin and, in some cases, prevent the
formation of F-actin in treated cells altogether, thereby precluding the
crucial cellular functions of microfilaments [4–6]. More than 60
different cytochalasins from several species of fungi have been
classified, and most appear to markedly affect actin polymerization
[1,5,7,8]. However, the most studied congener in regard to
antineoplastic activity has been cytochalasin B. As a microfilament-
disrupting agent, cytochalasin B alters many facets of cell physiology
dictated by F-actin, including cell motility, adherence, secretion, drug
efflux, deformability, morphology, and size, among many other
cellular properties [4,6,9]. Because of the importance of microfila-
ments in the formation and ingression of the cleavage furrow,
cytochalasin B is a potent inhibitor of cytokinesis and has been shown
repeatedly to selectively enlarge and multinucleate neoplastic cells
[10–14]. Such cells are ideal targets for microtubule-directed and
nucleic acid–directed agents, and drug synergy has been noted
between cytochalasin B and clinically approved antineoplastic agents
that act through these mechanisms [15–17]. Further, we have shown
that many cytochalasin congeners inhibit ATP binding cassette
transporter-mediated efflux (manuscript under review), tentatively
suggesting that cytochalasins and potentially other microfilament-
directed agents may be used to treat cancers refractory to normal
chemotherapy because of ATP binding cassette transporter-related
drug resistance.
In addition to our in vitrowork, we have extensively characterized the
in vivo activity of cytochalasin B against solid tumors and disseminated
cancers of murine origin [17–19]. Not only does cytochalasin B
significantly improve the lifespan of mice challenged with lung
carcinoma,melanoma, or leukemia, but long-term survival is frequently
observed [17–19]. Interestingly, cytochalasin B appears to have notable
efficacy against highly metastatic cell lines, having higher in vitro
cytotoxicity against cell lines selected for metastatic propensity than for
the original parental cancer cell line. In addition, cytochalasin B
substantially reduces the extent of metastases found in challenged mice
[17–19]. These observations are in accordance to the mechanisms of
cytochalasin congeners, as functioning microfilaments are essential for
neoplastic cell motility, invasion, and metastasis [20–24].
Due to the potential clinical importance that cytochalasin B and
other microfilament-directed agents may have and the large quantities
of these highly expensive agents needed for preclinical and clinical
study, we are disclosing our method of producing gram quantities of
cytochalasin B from Drechslera dematioidea so that interested
laboratories can reproduce and extend our findings. This purification
process also produces a smaller amount of cytochalasin A, which
demonstrates marked antineoplastic activity against drug sensitive and
resistant SK human ovarian carcinoma cell lines in vitro (manuscript
under review). In addition, we provide data relevant for characterizing
the tissue distribution of cytochalasin B administered as an
intravenous (i.v.) bolus dose. We also examine the routes of
administration and the maximum tolerated doses (MTDs) of
cytochalasin B in multiple murine models. This analysis includes
cytochalasin B that has been liposome encapsulated, as we havepreviously shown that this formulation reduces cytochalasin
B-associated immunosuppression while retaining marked antitumor
activity [19]. We then extend our previous in vivo findings by
examining the effects of a well-tolerated i.v. treatment protocol of
cytochalasin B in comparison with intraperitoneally (i.p.) adminis-
tered doxorubicin against M109 murine lung carcinoma growing as
an intradermal (i.d.) nodule in Balb/c mice. In addition, we
investigate the ability of subcutaneous (s.c.) cytochalasin B to
potentiate long-term survival (at least 53 days) in mice challenged
with the following murine neoplastic cell lines: M109 lung
carcinoma, Lewis lung carcinoma, LA4 lung adenocarcinoma,
B16F10 melanoma, and M5076 sarcoma. Finally, we characterize a
potential mechanism regarding how cytochalasin B reduces the
number of metastases found in treated mice by assessing the in vitro
effects of the agent on the secretion of N-acetylglucosaminidase
(GlcNACase) by B16BL6 and B16F10 melanoma cell lines.
Materials and Methods
Preparation of Agar and Media Used to Subculture D.
dematioidea for Inoculation of Large Mattes
Stocks of D. dematioidea (strain: IMI 74812) were acquired
commercially (ATCC 24346). Stocks were grown on slants of potato
dextrose agar and yeast extract (PDY). PDY was prepared in 250-ml
aliquots using 7.5 g potato dextrose agar, 1.25 g yeast extract, and
250 ml deionized, distilled water. The mixture was heated to near
boiling on a water bath while being magnetically stirred until all of the
solute dissolved. Five milliliters of PDY was added to 15-mm screw
top test tubes (8 ml for 18-mm tubes). The tubes were then
autoclaved for 30 minutes at a slow cooling rate (liquid cool) before
the tubes were slanted so that the media did not reach more than
halfway up the tube. The slants were then cooled, placed in an upright
position, and inoculated with D. dematioidea.
Growth of Large Mold Mattes of D. dematioidea
To prepare the growth media (Tanenbaum medium), 10 g bacto
soytone, 40 g dextrose, 20 g yeast extract, 150 g sucrose, and 1 l tap
water were added to a 2-l Erlenmeyer flask and then magnetically
stirred. Five-hundred-milliliter aliquots of media were then trans-
ferred to a large Pyrex dish. Media were then supplemented with 5
crumbled Shredded Wheat biscuits spread evenly across the dish.
Each dish was then covered with a double layer of aluminum foil and
autoclaved for 90 minutes at a slow cooling rate. This process was
then repeated to acquire 2-l Tanenbaum medium.
Mattes of D. dematioidea used for cytochalasin preparation were
grown in Tanenbaum medium using mold stocks that were the
lightest in color as they were the healthiest. Two to three PDY slants
were used to inoculate every 500 ml of Tanenbaum medium (2 l
total). Mattes were allowed to grow for 15 days on tissue culture
plates (20 mm × 245 mm × 245 mm) before being harvested for
cytochalasin preparation.
D. dematioidea is a Level 1 Biosafety agent and can be handled with
routine sterile procedures and protection from inhalation and
exposure to the eyes. Potential allergic responses to high levels of
mold spores encountered should be considered, and procedures
should be in place to manage any such occurrences.
MeOH Extraction of D. dematioidea
A total of 1.35 kg (wet weight) of healthy mold mattes were
lyophilized to acquire 420 g of dry mold. The mold was then blended
2 liters tanenbaum medium + Drechslera dematioidea
1.35 kg wet weight mold matte
420 g lyophilized mold
4 g CB extracted (by analysis)
99+% bound
3 g crude CB crystals
2 g CB crystals
700 mg CB + 90 mg CA
3 weeks
freeze dry
(lyophilization)
MeOH extraction (2x)
1) to 80% water
2) batch adsorption to C18 silica
1) hexane wash
2) elution with 1:1 hexane:THF
crystallization from chloroform
1) preparative TLC silica gel
linear K plates
2) MeOH elution of CB and CA
3) recrystallization (chloroform)
Figure 1. Preparation of cytochalasin B from D. dematioidea.
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before being vacuum filtered. The fraction was collected and then set
aside. The process was then repeated but only with enough MeOH to
put the mold into suspension. The first and second filtrates were then
combined to give a total volume of 3 to 4 l. Regular-phase thin layer
chromatography (85:15 toluene:MeOH eluent) was used to
determine the composition and purity of this crude extract against
a small amount of commercially purchased cytochalasin B (Sigma-
Aldrich Corp., St. Louis, MO). Water was then added to the filtrates
to obtain an 80:20 H2O:MeOH mixture, bringing the total volume
to 12 to 16 l.
Reversed-Phase Thin Layer Chromatography to Acquire
Purified Cytochalasin Extract
The 80:20 H2O:MeOH eluate was subjected to reversed-phase
thin layer chromatography with 50 g octadecyl carbon chain (C18)–
bonded silica gel mixed with 100 ml MeOH. The column was then
air dried for 2 minutes under water aspiration before the column was
placed in a dessicator with P2O5 and vacuum pumped overnight. The
column was then washed with 100 ml hexane before a 200-ml
hexane/200-ml 60:40 THF:hexane mixture was used to elute
cytochalasin B from the column; eluate was collected as 10-ml
fractions. Commercially purchased cytochalasin B was again used to
assess the purity of the product using regular-phase thin layer
chromatography. Filtrates were then vacuum filtered to acquire
precipitant, which was then stored in a dessicator with P2O5.
Precipitates containing yellow color were purified in hot THF
(2-3 ml hot THF per 200 mg precipitate) and eluted through a
column containing a 100-g silica, 100-ml 1:1 EtOAc:hexane slurry.
The plug filtrate was then evaporated until a precipitate formed. This
precipitate was then dissolved in heated chloroform, resulting in the
formation of crystalline cytochalasin.
Purification of Cytochalasin Crystals Using
Flash Chromatography
Cytochalasin B crystals were dissolved in THF and subjected to
flash chromatography using a 150-g silica, 150-ml 1:1 EtOAc:hexane
slurry and 350 ml 1:1 EtOAc:hexane as the eluent. Thirty 10-ml
fractions were collected and stored at 4°C overnight before being
vacuum filtered to collect precipitates. Cytochalasins A and B were
then separated using Whatman preparative thin layer chromatogra-
phy plates (Fisher Scientific International Inc., Hampton, NH). Two
distinct bands were then observed, indicating that cytochalasin A (top
band) had separated from cytochalasin B (bottom band). These bands
were then eluted from the silica using 2 to 3 ml MeOH at a time. The
purity of cytochalasins A and B was analyzed using 1H NMR
spectroscopy (spectra not shown). The steps necessary for successful
extraction and purification of cytochalasins A and B from mattes of
D. dematioidea are succinctly highlighted in Figure 1.
Cytochalasin B and Doxorubicin Formulation
and Administration
Cytochalasin B was prepared in suspension form in 2%
carboxymethyl cellulose 1% Tween 20 (CMC/Tw) and in solution
in dimethyl sulfoxide (DMSO) and 33% ethanol:0.9% NaCl
solution as previously described [17–19]. In addition, cytochalasin
B was liposome encapsulated in unilamellar vesicles of egg
phosphatidylcholine:dimyristoylphosphatidylglycerol using methods
previously described [19]. Doxorubicin was prepared in solution
using the 33% ethanol:0.9% NaCl solution.Suspension formulations of cytochalasin B required that the agent
was emulsified in the CMC/Tw vehicle. This was accomplished by
dissolving 1 ml Tween 20 into 90 ml pyrogen-free water before
adding 2 g carboxymethyl cellulose sodium salt. The mixture was
stirred with a magnetic stirrer for ~1 hour before being added to 9 ml
distilled water to make a 2% carboxymethyl cellulose/1% Tween 20
vehicle. Cytochalasin B was then added to a sterile plastic syringe
before CMC/Tw was added to a second syringe. The hubs of a
22-gauge emulsifying needle were attached to each syringe. The
vehicle was gently pushed into the cytochalasin B–containing syringe
and then slowly shaken. After the suspension passed through the
22-gauge needle, the suspension was passed through a 25-gauge
needle with an air bubble of ~0.5 ml kept in the storage syringe to
resuspend cytochalasin B before the next transfer to the injection
syringe. The emulsified cytochalasin B was then kept in the original
syringe, lying on its side in a refrigerator at 4°C for 12 hours.
Afterward, cytochalasin B–CMC/Tw was lightly shaken to resuspend
the agent and then reemulsified through a 25-gauge needle before
being capped before use.
Preparation of Cytochalasin B with 3H-Labeled
Phenylmethyl Group
3H-labeled cytochalasin B was prepared to determine the
distribution of the agent in Balb/c mice, as assessed by high-
performance liquid chromatography (HPLC). Before the inoculation
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supplemented with 2 mCi [3H] phenylalanine (side chain 3H,
15 Ci/mol, in sterile ethanol:water, from ICN) in 500 ml of
medium, along with one crushed wheat biscuit. The purified product
was again subjected to preparative thin layer chromatography in
reduced light and was eluted with methanol before use to prevent the
formation of cytochalasin A over time.
Conversion of M109 to Continuous Culture (M109c)
M109 murine lung carcinoma cells were converted to continuous
culture using methods previously described [17]. As in the previous
papers of this series [17–19], comparison between animals challenged
i.d. with M109c cells and matched groups challenged with in vivo
passagedM109 cells showed that the challenges were indistinguishable
in terms of growth kinetics, invasion, metastasis, and host survival.
Solid Tumors In Vivo
M109 murine lung carcinoma was maintained as a spontaneously
invasive and metastatic model by serial passage s.c. in Balb/c mice as
previously detailed [19], with the passage challenge being 2 × 105
trypan blue–negative cells. For chemotherapy testing, Balb/c mice
under isoflurane anesthesia (Sigma-Aldrich Corp.) were challenged
i.d. on the lower right ventral quadrant over the peritoneum after first
removing hair with a chemical depilatory agent. The challenge dose
was 2 × 105 trypan blue–negative cells in a volume of 200 μl. Tumor
cells were obtained from early s.c. tumor in vivo passaged donors
(M109) or from continuous cultures of M109 lung carcinoma cells
(M109c). Tumor growth was monitored by daily caliper measure-
ments, which were facilitated by the localized growth of the i.d.
challenge contained entirely in a region initially free of hair. Effects on
primary tumor appearance, growth rate, invasion, and metastases to
the lungs, liver, kidneys, pancreas, and spleen were determined as
previously detailed for s.c. challenges with M109 tumor [18].
The other solid tumor lines (Lewis lung, LA4, B16F10, and
M5076) were given as a 1 × 106 cell challenge s.c. in Balb/c, C57BL6,
or B6D2F1 mice. The procedures for measuring tumor growth were
the same as with M109 lung carcinoma.
Statistics
Survival analysis used the Cox-Mantel test as detailed by Lee [26].
Effects on tumor growth rates were evaluated by repeated-measures
analysis of variance using SAS (Cary, NC) software. Tests of
hypotheses for between-subject effects were applied, and of time
versus group interactions using the Geisser-Greenhouse adjustment
in cases where tests of orthogonal components showed absence of
sphericity. Differences in lung metastases between treated and
control groups were evaluated with a Student-Fisher t test.
Analysis ofN-AcetylglucosaminidaseActivity inB16BL6andB16F10
Murine Melanomas after Administration of Cytochalasin B
B16BL6 and B16F10 murine melanomas were cultured using
methods previously described [17,19].Cells were subcultured when
they reached 1 × 106 cells/ml. The confluent monolayer was treated
with 0.2% trypsin-EDTA solution 10× (Sigma-Aldrich Corp.) for
1 minute at 37°C, and the suspended cells were seeded at 4 × 104 cells/
cm2 in 25-cm2 culture flasks. Cells were allowed to attach before being
treated with 0.1 or 1 μM cytochalasin B for 48 hours. GlcNACase
activity of untreated and cytochalasin B-treated cells was assessed as
previously described [27].Results
Preparation of Cytochalasins A and B
Procedures shown in Figure 1 produced 700 mg of HPLC-pure
cytochalasin B and 90 mg of HPLC-pure cytochalasin A. Purity was
N99%. Rf values corresponded to commercially obtained congeners,
and 1H NMR spectra were in accordance with expected peak values.
Crystalline cytochalasin B had a melting point of 216°C to 218°C
(commercial cytochalasin B: 217°C to 220°C; literature reference
melting points range from 215°C to 223°C) and showed no evidence
of fluorescence quenching, iodine vapor positive contaminants, or
p-anisaldehyde–positive contaminants when 100 μg was analyzed
by thin layer chromatography, indicative of a highly pure product.
The radioactive labeling procedure produced 30 mg 3H labeled
cytochalasin B at the phenylmethyl group that was N99% pure as
assessed by analytical thin layer chromatography, radiochromatogra-
phy, and 1H NMR spectroscopy. Specific activity was 3 μCi/mmol.
Tissue Distribution of Intravenously Administered
Cytochalasin B in Balb/c Mice
3H-labeled 3.5 mg/kg cytochalasin B was administered as an i.v.
bolus dose in Balb/c mice at time 0 and followed over the course of
720 minutes. The total dose per mouse was 70 μg (3.5 μg/g). Tissue
distribution revealed that the agent has a marked affinity for the
intestines, as 8.75 μg/g tissue was present 30 minutes postinjection
and 1.5 μg/g tissue remained after 180 minutes (Figure 2A).
Furthermore, it appears that cytochalasin B remains in the intestines
for some time, as 0.58 μg/g tissue remained after 720 minutes
(Figure 2A). The 6 tissues out of the 12 analyzed that had the highest
levels of cytochalsin B at time 0 or at 15 minutes after i.v. treatment
are shown in Figure 2A. The five highest concentrations at 15 minutes
were in the liver, lungs, intestines, pancreas, and tail (2.8 to 4 μg/g
tissue). The kidneys had an initial concentration of 3 μg/g at the time
of injection, but showed only 0.4 μg/g at 15 minutes. The six tissues
with the lowest distributions at 15 or 30 minutes included the heart,
ovaries, spleen, bladder, and stomach. Very little cytochalasin B was
detected in the brain initially (0.25 μg/g tissue) or at any time from 15
to 180 minutes (Figure 2A). Interestingly, tissues appeared to follow
two types of distribution; either cytochalasin B reached peak
concentrations shortly after administration, followed by a gradual
decrease (liver, tail, lungs, kidneys, and pancreas), or cytochalasin B
concentrations spiked at 30 minutes, followed by a gradual decrease
(intestines, heart, spleen, ovaries, and bladder).
Analysis of cytochalasin B tissue distribution was then extended to
24 hours using a 5-mg/kg i.v. bolus dose, which is equal to 5 μg/g, or
a 100-μg total dose for a 20-g mouse (Table 1). Interestingly, the
concentration of cytochalasin B in the lungs was markedly increased
with this higher dose at 30 minutes (0.8 μg/g tissue with 3.5 mg/kg
and 11.1 μg/g tissue with 5 mg/kg). In addition, the plasma
concentration of cytochalasin B steadily declined over the course of
24 hours, and it appears that the t1/2 of an i.v. bolus dose in the blood
is between 0.5 and 12 hours in Balb/c mice. The highest tissue
concentrations at 30 minutes in Table 1 were recorded in the lungs,
intestines, and liver (3 μg/g to 11 μg/g), in agreement with
observations made in Figure 2A for the six highest tissues. The
heart, spleen, ovaries, kidney, bladder, and stomach were among the
tissues with the lowest distribution at 30 minutes in Table 1, again
consistent with observations in these tissues for a lower dose of
cytochalasin B shown in Figure 2A. Table 1 also shows tissue
Figure 2. Tissue distribution of 3H-labeled 3.5 mg/kg cytochalasin B administered as an i.v. bolus dose in Balb/c mice over the course of
720 minutes. (A) Distribution in nonneoplastic tissues. (B) Distribution in an i.d. tumor of M109 murine lung carcinoma. Analyses were
performed by analytical HPLC.
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examined among the 12 tissues shown in Figure 2A. Cytochalasin B
remaining in the tail was not examined among the tissues shown in
Table 1. It is important to note that, even at this higher concentration
of cytochalasin B, concentrations in the brain never rose aboveTable 1. Tissue Distribution of 3H-Labeled cytochalasin B Administered as a 5-mg/kg i.v. Bolus
dose, 100 μg/20 g Mouse, in Balb/c Mice
μg CB/g Tissue
Tissue 0.5 Hour 12 Hours 24 Hours
Lungs 11.1 9.1 0.99
Intestine 8.8 0.73 0.87
Liver 3.04 0.32 0.05
Stomach 1.79 0.26 0.7
Renal lipids 1.3 2.4 0.68
Bladder 0.75 0.82 0.60
Lymph nodes 0.69 0.64 0.36
Kidney 0.64 0.12 0.08
Ovaries 0.64 0.40 0.28
Spleen 0.58 0.42 0.20
Thymus 0.49 0.52 0.41
Heart 0.45 0.24 0.19
Pancreas 0.23 0.21 0.12
Brain 0.06 0.08 0.07
Blood 0.13/ml 0.04/ml 0.02/ml
Tissues are ordered in descending order of concentration at 0.5 hour other than blood, which is
measured per ml.0.08 μg/g tissue. The potential therapeutic implications of this
observation will be elaborated upon in the discussion.
When Balb/c mice were challenged i.d. with M109 lung carcinoma
and treated with 3.5 mg/kg i.v. bolus cytochalasin B, the agent
appeared to have affinity for the tumor that was in the range exhibited
in Figure 2A and Table 1 by normal tissues with intermediate
cytochalasin B distribution such as the bladder, lymph nodes,
thymus, kidney, ovaries, spleen, and heart (Figure 2B). Peak
cytochalasin B concentration in the tumor nodule was 0.68 μg/g
tissue 5 minutes postinjection and remained above 0.55 μg/g for at
least 30 minutes. As with normal tissue, the concentration of
cytochalasin B appeared to gradually decrease between 180 and
720 minutes, demonstrating that the agent remains in neoplastic
tissue for at least 12 hours after i.v. bolus administration. A
concentration of 0.2 μg cytochalasin B/g tumor at 3 hours
corresponds to a concentration of 50 μM cytochalasin B, assuming
a 1-ml volume/g tumor. This is ~25-fold higher than the bioactive
concentration of cytochalasin B in vitro against M109c lung
carcinoma at 3 hours [17].
Maximum Tolerated Dose of Cytochalasin B Using Various
Routes of Administration and Formulations in Multiple
Murine Models
The MTDs of cytochalasin B in suspension, solution, or liposome
encapsulation administered i.p., i.v., or s.c. in Balb/c, B6D2F1,
Table 2. Maximum Tolerated Doses of Nonencapsulated Cytochalasin B and Liposomal
Cytochalasin B Administered i.p., i.v., and s.c. in Balb/c, B6D2F1, CD2F1 *, and C57B1/6 Mice
Route Vehicle Formulation Schedule
(Days)
mg/kg Max. Wt.
Loss (%)
Drug
Deaths
i.p. CMC/Tw Suspension 1 50 7 2/34
CMC/Tw Suspension 1, 4, 7 50/day 6 0/16
DMSO Solution 1 25 2 1/5
CMC/Tw Liposome 1 400 2 0/40
s.c. CMC/Tw Suspension 1 100 3 0/31
CMC/Tw Suspension 1 150 7 4/28
DMSO Solution 1 100 7 5/32
CMC/Tw Liposome 1 N500 7 0/25
i.v. CMC/Tw Suspension 1 20 1 0/10
EtOH/Sal Solution 1 10-20 1-2 1/20
CMC/Tw Liposome 1 25 1 0/10
Max. Wt. Loss: maximum weight loss experienced after receiving the indicated dose.
* CD2F1mice could only tolerate 10 mg/kg i.v. as a bolus injection and had a maximumweight loss of 2%.
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administered i.p. or s.c., a lower MTD of cytochalasin B is reached
with the agent in solution (25 mg/kg and 100 mg/kg) rather than in
suspension (50 mg/kg and 150 mg/kg). Nevertheless, equal doses of
cytochalasin B in suspension or solution can be administered i.v. to
mice (20 mg/kg). It should be noted that CD2F1 mice could tolerate
only 10 mg/kg i.v. as a bolus injection. The maximum weight loss
experienced during i.p. and s.c. administration ranged from 2% to
7%, and for i.v. administration, it ranged from 1% to 2%.
As previously demonstrated in [19], the MTD of cytochalasin B
could be dramatically increased through liposome encapsulation.
Whereas the i.v. MTD of liposomal cytochalasin B increased only by
5 mg/kg (20 to 25 mg/kg), the i.p. MTD increased by 8-fold (50 to
400 mg/kg), and the s.c. MTD increased by more than 3-fold (150 to
N500 mg/kg). Furthermore, the maximum % weight loss after
administration of the MTD of liposome encapsulated cytochalasin B
was decreased for i.p. administration and remained equal for s.c. and
i.v. administration when comparing liposome-encapsulated and
nonencapsulated cytochalasin B. A previous study has shown that
cytochalasin B–induced immunosuppression is partially reversed
when cytochalasin B is administered in liposomal form [19].
Effects of Intravenously Administered Cytochalasin B
and Intraperitoneally Administered Doxorubicin on M109c
Murine Lung Carcinoma Challenged Mice
Administration of cytochalasin B as a 5-mg/kg/day i.v. bolus dose
on days 1 to 5 to Balb/c mice challenged i.d. with 2 × 105 M109c
cells appeared to markedly perturb tumor growth (Figure 3A). At
30 days postchallenge, cytochalasin B–treated mice had a mean
tumor volume of 0.53 cm3 (standard error of the mean; SEM =
0.04), whereas mice treated with the vehicle had a mean tumor
volume of 0.9 cm3 (SEM = 0.034). Doxorubicin administered as a
5-mg/kg i.p. dose once or twice had a notable antitumor effect, but it
was not as pronounced as cytochalasin B (Figure 3A). These effects on
tumor growth appear to be supported by the long-term survival
potentiated by the 5-mg/kg/day i.v. bolus cytochalasin B treatment
protocol (Figure 3B). There was a 50% survival rate at least up to day
53 for mice challenged with an i.d. tumor nodule in the cohort treated
five times with 5-mg/kg i.v. bolus cytochalasin B (n = 16). This is a
highly significant prolonging of life expectancy, as all mice treated
with the vehicle were dead by day 42 (n = 10). By contrast, mice
treated once with 5 mg/kg i.p. doxorubicin were all dead by day 50
(n = 10), and only 1 in 10 mice treated twice with 5 mg/kg i.p.doxorubicin was alive after 53 days. These data are further supported
by a Cox-Mantel test that indicated a P b .05 for each treatment
cohort.
In addition, the same dose of cytochalasin B markedly reduced the
extent of terminal lung metastases observed in Balb/c mice challenged
with a single i.d. tumor inoculation (Figure 3C). As previously
mentioned [19], mice challenged i.d. with M109c lung carcinoma
present significant metastases only in the lungs. The effects of
cytochalasin B on reduction in lung metastases appear to be dose
dependent, as demonstrated when the 5-mg/kg i.v. bolus dose was
administered daily one to five times (Figure 3C). Mice bearing an i.d.
tumor and treated with 1, 2, 3, 4, or 5 peritumoral doses of
cytochalsin B showed a clear dose-dependent response with a 90%
reduction in lung metastases at the terminal stages in the mice
receiving five doses of cytochalasin B peritumorally. The cohort of
mice treated with i.v. cytochalasin B 5 mg/kg/day for 5 days had a
mean of seven nodules (SEM = 2.8), whereas the cohort treated with
the vehicle only had a mean of 62 nodules (SEM = 5.4). These effects
on terminal lung metastases were significantly different compared
with the two doxorubicin cohorts, as mice treated with 5 mg/kg i.p.
doxorubicin on day 1 had a mean of 57 nodules (SEM = 3.2),
whereas those treated with the same dose on days 1 and 3 had a mean
of 50 nodules (SEM = 4.9).
Effects of Cytochalasin B on Prolonging the Survival of Mice
Challenged with Various Solid Tumors
Cytochalasin B administered s.c. as a 100-mg/kg dose on day 1
appeared to have marked antineoplastic activity against most of the
solid tumor challenges (Figure 4), as a significant proportion of the
mice lived at least 53 days after the initial tumor challenge: M109
lung carcinoma (4/10 mice), Lewis lung carcinoma (5/10 mice), LA4
lung adenocarcinoma (6/10 mice), and B16F10 melanoma (4/10
mice). Although 100 mg/kg cytochalasin B s.c. significantly
prolonged the survival of mice challenged with M5076 sarcoma in
comparison with the vehicle-only treated mice, all mice in this cohort
were dead by day 30; the treatment was unable to produce any
long-term survivors at day 53 (0/10 mice), and all mice were dead by
day 44 (Figure 4).
Effects of Cytochalasin B on N-Acetylglucosaminidase Activity
in B16BL6 and B16F10 Murine Melanomas
Before administration of cytochalasin B, B16BL6 and B16F10
melanomas had an extracellular percentage of GlcNACase compared
with total enzyme activity ranging from 27% to 41% (Table 3). A
total of 0.1 μM cytochalasin B administered for 48 hours decreased
this range to 23% to 28%. One micromolar of cytochalasin B
administered for the same length of time further reduced this range to
12% to 27%. Interestingly, cytochalasin B appeared to have no
influence on the total amount of GlcNACase in either cell line,
suggesting that cytochalasin B may inhibit the secretion of GlcNA-
Case and potentially other glucosaminidases. The importance of
inhibiting the secretion of glucosaminidases in neoplastic cells will be
elaborated upon in the discussion.
Discussion
In the present study, we have demonstrated that cytochalasin B can be
safely given to murine models through multiple routes of
administration. As previously shown [17,18], cytochalasin B can be
administered i.p., i.v., and s.c. in Balb/c mice, with the MTD being
higher using a suspension (CMC/Tw) rather than solution vehicle
Figure 3. Effects of cytochalasin B administered five times as a 5-mg/kg i.v. bolus dose and doxorubicin administered once or twice as a
5-mg/kg i.p. dose on M109 murine lung carcinoma. (A) Effects on the long-term growth of established M109c i.d. tumor nodules.
Cytochalasin B was administered on days 1 to 5 following tumor challenge. Doxorubicin was administered on day 1 and on days 1 and 3
following tumor challenge. There were 16 mice in the CB-treated cohort, 10 mice in both doxorubicin-treated groups, and 10 mice in the
cohort that received only the vehicle. The CB-treated group was significantly different from the control and doxorubicin-treated groups;
P b .01 for between-subject effects, P b .05 for time versus group interactions. Bars reflect SEM of the treatment groups. (B) Effects of
cytochalasin B administered as a 5-mg/kg i.v. bolus dose and doxorubicin as a 5-mg/kg i.p. dose on the survival of Balb/c mice challenged
with M109c lung carcinoma. Survival of mice treated with cytochalasin B (n = 16) was significantly different from that of mice receiving
the doxorubicin regimens (n = 10 for both groups) or only the vehicle (n = 10); P b .05, as assessed by a Cox-Mantel test. (C) In vivo
activity of cytochalasin B administered as a 5-mg/kg i.v. bolus dose or doxorubicin administered as a 5-mg/kg i.p. dose against the
metastatic spread of M109c lung carcinoma. Size of all treatment groups is indicated in the figure. The lungs were the only tissue that
contained substantial metastases. Bars reflect SEM of each treatment group.
314 Preparation and Properties of Cytochalasin B Trendowski et al. Translational Oncology Vol. 8, No. 4, 2015(DMSO) for i.p. and s.c. administration (Table 2). However, the
EtOH/saline solution produced as high an MTD as did CMC/Tw
suspension when administered as an i.v. bolus dose (20 mg/kg), with
the exception of CD2F1 mice that could tolerate only 10 mg/kg
cytochalasin B. In [19], we demonstrated that liposome-encapsulated
cytochalasin B could dramatically increase the MTD of the agent
when administered i.p. We have now demonstrated that liposome-
encapsulated cytochalasin B increases the MTD of i.v. and s.c.
administered cytochalasin B (20 to 25 mg/kg i.v. and 100 to
N500 mg/kg s.c.). In addition, we demonstrated that liposome-
encapsulated cytochalasin B can be safely administered i.p. at
400 mg/kg, an eight-fold higher dose than can be used with non–
liposome-encapsulated cytochalasin B.
We have previously characterized the pharmacokinetics and tissue
distribution of nonencapsulated and liposome-encapsulated cytochalasinB administered i.p [19,25]. The present study extended these analyses to
i.v. nonencapsulated cytochalasin B. Although there has been concern
that cytochalasin B could have potential cardiotoxicity in vivo[28,29], the
relatively low tissue concentration of cytochalasin B found in this organ
after i.v. bolus administration 0 to 24 hours postinjection (Figure 2 and
Table 1), combined with the low rate of drug-related deaths at notably
high drug concentrations of cytochalasin B using multiple routes of
administration (Table 2), suggests that cytochalasin B does not elicit
cardiotoxicity to any significant degree when administered as an i.v. bolus
dose. This is important, as cytochalasin B has shown marked drug
synergywithmultiple nucleic acid–directed agents including doxorubicin
[17], amember of the anthracycline drug class that is noted for substantial
cardiotoxicity [30]. Therefore, the concomitant administration of
cytochalasin B and anthracyclines remains a feasible combination for
evaluating antineoplastic activity in murine models.
Figure 4. Effects of cytochalasin B administered once as a 100-mg/kg
s.c. dose on potentiating long-term survival in mice challenged with
various solid tumors. Mice were challenged i.d. with M109 lung
carcinoma and s.c. with Lewis lung carcinoma, LA4 lung adenocar-
cinoma, B16F10 melanoma, or M5076 sarcoma. In each challenge,
the survival of tumor-bearing mice treated with cytochalasin B
(denoted by CB) was significantly different than the vehicle-only–
treated group (denoted by V); P b .05, as assessed by a Cox-Mantel
test. There were 10 mice for all cohorts.
Table 3. Effects of Cytochalasin B on Secretion of N-Acetylglucosaminidase by B16BL6 and
B16F10 Murine Melanomas In Vitro
A B C D E F G
CB 48 h
(μM)
Ex-Cell
GlcNACase
(Units/mg)
In-Cell
GlcNACase
(Units/mg)
Total
GlcNACase
(B + C)
Ex-Cell %
of Total
GlcNACase
In-Cell %
of Total
GlcNACase
Total
GlcNACase
(% of Ctrl)
B16BL6
0 315 840 1155 27 73 100
0.1 288 969 1257 23 77 109
1 175 1260 1435 12 88 124
0 748 1084 1832 41 59 100
1 565 1486 2051 27 73 112
B16F10
0 1065 2273 3338 32 68 100
0.1 951 2406 3357 28 72 101
0 932 2004 2936 32 68 100
1 420 2635 3055 14 86 104
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5.0-mg/kg cytochalasin B bolus i.v. administered once a day for 5
consecutive days, there was a noticeable increase in the concentration
of cytochalasin B in the lungs when the concentration was increased
from 3.5 to 5 mg/kg [0.04 μg/g tissue after 12 hours (720 minutes)
vs 9.1 μg/g tissue after 12 hours]. Such a marked increase in tissue
concentration of cytochalasin B in the lungs after only a small dosage
increase is notable and may raise concern for potential pulmonary
toxicity. Nevertheless, i.v. cytochalasin B was tolerated in suspension
at 20 mg/kg as a bolus dose and increased to 25 mg/kg after liposome
encapsulation. Therefore, it may be possible to combine cytochalasin
B with nucleic acid–directed agents that exhibit marked pulmonary
toxicity, such as bleomycin [30], without subjecting tumor-bearing
mice to intolerable side effects.
In addition to its concentration in normal tissue, it appears that i.v.
cytochalasin B readily infiltrates neoplastic tissue, as demonstrated
with M109 lung carcinoma (Figure 2B). The concentration of
cytochalasin B in M109 tumor nodules leveled off between 180 and
720 minutes, indicating that sustained levels of the agent can be
found in malignant growths 12 hours after a single i.v. bolus
administration of 3.5 mg/kg. These data indicate that cytochalasin B
can reach its intended target and remain in significant concentration
hours after administration. Nevertheless, we have demonstrated that
cytochalasin B can exert antitumor activity in M109 lung carcinoma
without having to be in direct contact with the tumor nodule [19],
and direct cytotoxicity may not be necessary for significant
cytochalasin B–mediated tumor regression.
Cytochalasin B is a notably lipophilic compound, suggesting that it
might be considered for use as an i.v. administered agent to cross the
lipophilic blood brain barrier (BBB) in brain cancer chemotherapy.
However, HPLC analysis of 3H-labeled cytochalasin B revealed that
the agent does not reach high tissue concentrations in the brain when
administered i.v. (0.06 μg/g tissue 30 minutes after a 5.0-mg/kg
dose). This is likely due to the relatively high molecular weight ofcytochalasin B (MW = 479.6), as bulky compounds have difficulty
traversing the BBB [30]. For comparison, the lipophilic alkylating
agent temozolomide, which is known to readily cross the BBB, has an
MW = 194.151. Nevertheless, these low concentrations of cytocha-
lasin B may still exhibit notable in vivo antineoplastic activity against
brain tumors, or it may be possible to administer cytochalasin B
intrathecally into mammalian preclinical models to assess its efficacy
against brain tumors. These studies are currently under way in
our laboratory.
In [17–19], we demonstrated that cytochalasin B has marked
in vivo antineoplastic activity in murine models challenged with solid
localized tumors, as well as against disseminated cancers. In this study,
we confirmed that cytochalasin B markedly affects the progression of
M109 lung carcinoma (Figure 3A) and can produce long-term
survival when administered i.v. or s.c. (8/16 mice treated i.v. were
alive at 53 days, whereas 4/10 mice treated s.c. were alive at 53 days;
Figures 3B and 4, respectively). These effects were comparable to
doxorubicin administered once or twice as a 5-mg/kg i.p. dose
(Figure 3), indicative of the marked antitumor activity elicited by
cytochalasin B in the M109 tumor model system. In addition, it
appears that cytochalasin B has marked cytotoxicity for metastatic
cells, as the agent reduced the number of M109c lung metastases
from a mean of 62 nodules when treated only with an EtOH/saline
vehicle to a mean of 7 nodules when treated five times with 5-mg/kg
cytochalasin B i.v. bolus (Figure 3C). The reduction of metastases was
greater than 5 mg/kg doxorubicin i.p., which had a mean of 57
nodules with only one injection, and a mean of 50 nodules after two
injections (Figure 3C). Further, the reduction in lung metastases
potentiated by cytochalasin B appeared to be dose dependent, further
confirming the antitumor activity the agent has toward metastatic
cells. These effects on reduction in metastatic nodules are very similar
to our observations in [17,18], indicating that cytochalasin B can
inhibit metastatic progression in tumor-bearing murine models.
Although we have previously demonstrated the antitumor activity
of cytochalasin B in vivo against M109 lung carcinoma, B16F10
melanoma, and P388/S and P388/ADR leukemia [17–19], we have
now extended these observations to Lewis lung carcinoma and LA4
adenocarcinoma. These data suggest that cytochalasin B is notably
active against murine lung cancers and that investigating its potential
in human lung tumor xenograft models is warranted. It is also
important to note that although cytochalasin B was able to prolong
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unable to produce any long-term survivors at day 53. This is an initial
indication of the type of malignancies that cytochalasin B may not be
efficacious for, but certainly does not preclude its examination in
other sarcoma models.
Previously, we have demonstrated that cytochalasin B has a marked
increase in cytotoxicity in vitro against murine melanoma cells
selected by in vivo serial passage for an increased propensity to
metastasize [17]. When combined with our data on in vivometastases
reduction, it appears that metastatic cells are particularly sensitive to
cytochalasin B. These observations are in accordance with the
importance of microfilaments in motility and invasion
[31,24,23,32,33]. Significantly inhibiting actin polymerization
would likely inhibit the rate at which neoplastic cells metastasize
and therefore highlights the potential utility of microfilament-
disrupting agents in the clinical setting. The utility of cytochalasin B
in antimetastatic therapy may extend further than inhibiting the
motility of highly malignant cells, as demonstrated by the ability of
the agent to disrupt the secretion of GlcNACase in B16BL6 and
B16F10 melanoma cells (Table 3). GlcNACase and other glycosi-
dases are used by metastatic cells to degrade the carbohydrate
polymers that mask the protein backbone of the extracellular matrix,
enabling nearby proteases to provide the physical space needed for
malignant cell migration [34–37]. Inhibiting the secretion of
glycosidases by metastatic cells would reduce the extent of
carbohydrate degradation, thereby reducing the efficacy of proteases
to clear a navigable path to the vasculature necessary for intravasation.
Conclusion
Cytochalasin B, its congeners, and other microfilament-directed
agents comprise a potentially novel class of chemotherapeutic agents,
as they have shown in vitro and in vivo efficacy against many forms of
malignancy [1]. The method by which our laboratory extracts
cytochalasins A and B from D. dematioidea is provided so that other
interested laboratories can evaluate and extend our findings and
contribute additional preclinical evidence to warrant clinical
examination. This method is cost effective and substantially decreases
the expense of in vivo work involving cytochalasins A and B. To
compare, a matte of D. dematioidea can produce the gram quantities
of cytochalasins A and B needed for extensive mammalian study for
less than $400 (420 g dry mold produces ~700 mg cytochalasin B
and 90 mg cytochalasin A). By contrast, 10 mg cytochalasin A and
50 mg cytochalasin B from a commercial supplier can cost around
$633.00 and $1245.00, respectively. In addition, partial or total
syntheses of cytochalasins have been described [38–40] and are
another alternative to commercial purchases. Although it is true that
most promising drug leads fail to exhibit clinical efficacy,
microfilament-directed agents have yet to be critically evaluated in
controlled clinical trials. Critical assessment of these novel antineo-
plastic agents is indeed warranted and hopefully will establish a new
avenue of chemotherapy.
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